RU98102450A - Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания - Google Patents
Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыханияInfo
- Publication number
- RU98102450A RU98102450A RU98102450/14A RU98102450A RU98102450A RU 98102450 A RU98102450 A RU 98102450A RU 98102450/14 A RU98102450/14 A RU 98102450/14A RU 98102450 A RU98102450 A RU 98102450A RU 98102450 A RU98102450 A RU 98102450A
- Authority
- RU
- Russia
- Prior art keywords
- delivery system
- drug delivery
- therapeutic compound
- group
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 15
- 230000001225 therapeutic Effects 0.000 title claims 10
- 230000035812 respiration Effects 0.000 title 1
- 230000029058 respiratory gaseous exchange Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drugs Drugs 0.000 claims 11
- 239000002552 dosage form Substances 0.000 claims 5
- 239000002502 liposome Substances 0.000 claims 5
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 230000003364 opioid Effects 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 229960004715 Morphine Sulfate Drugs 0.000 claims 3
- 230000000202 analgesic Effects 0.000 claims 3
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 claims 3
- 239000003076 neurotropic agent Substances 0.000 claims 3
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 2
- 229960001113 Butorphanol Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229960002428 Fentanyl Drugs 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
- 229960003406 Levorphanol Drugs 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 2
- 229960004739 Sufentanil Drugs 0.000 claims 2
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 claims 2
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 229960000240 hydrocodone Drugs 0.000 claims 2
- 229960001410 hydromorphone Drugs 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- -1 nalbupine Chemical compound 0.000 claims 2
- 239000003401 opiate antagonist Substances 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 229960005118 oxymorphone Drugs 0.000 claims 2
- 229960005301 pentazocine Drugs 0.000 claims 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 229960001391 Alfentanil Drugs 0.000 claims 1
- 108010049140 Endorphins Proteins 0.000 claims 1
- 102000009025 Endorphins Human genes 0.000 claims 1
- 108010092674 Enkephalins Proteins 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 108050003490 Insulin-like growth factor Proteins 0.000 claims 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 Naloxone Drugs 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 Naltrexone Drugs 0.000 claims 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N Neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 claims 1
- 229960002362 Neostigmine Drugs 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 108010008267 Nerve Growth Factors Proteins 0.000 claims 1
- 229960002748 Norepinephrine Drugs 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 229960003692 aminobutyric acid Drugs 0.000 claims 1
- 230000000975 bioactive Effects 0.000 claims 1
- 230000001886 ciliary Effects 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 239000011528 polyamide (building material) Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
Claims (33)
1. Способ эпидурального введения терапевтического соединения позвоночному, включающий инкапсулирование соединения в системе доставки лекарственного средства, имеющей поддерживаемую скорость высвобождения соединения, и эпидуральное введение системы доставки лекарственного средства позвоночному.
2. Способ по п. 1, в котором позвоночное является млекопитающим.
3. Способ по п. 2, в котором млекопитающее является человеком.
4. Способ по п. 1, в котором систему доставки вводят в виде разовой дозы.
5. Способ по п. 1, в котором система доставки лекарственного средства является дисперсной системой.
6. Способ по п. 5, в котором система доставки лекарственного средства содержит лекарственную форму на липидной основе.
7. Способ по п. 5, в котором система доставки лекарственного средства содержит липосомную лекарственную форму.
8. Способ по п. 5, в котором система доставки лекарственного средства содержит мультивезикулярную липосомную лекарственную форму.
9. Способ по п. 7 или 8, в котором терапевтическое соединение является опиоидом.
10. Способ по п. 7 или 8, в котором терапевтическое соединение является пептидом или пептидомиметиком.
11. Способ по п. 9, в котором терапевтическое соединение является морфинсульфатом.
12. Способ по п. 9, в котором терапевтическое соединение является гидроморфоном.
13. Способ по п. 7 или 8, в котором терапевтическое соединение выбирают из группы, состоящей из кодеина, гидрокодона, леворфанола, оксикодона, оксиморфона, диацетилморфина, бупренорфина, налбупина, буторфанола, пентазоцина, метадона, фентанила, суфентанила и алфентанила.
14. Способ по п. 7 или 8, в котором терапевтическое соединение выбирают из группы, состоящей из энкефалинов, эндорфинов, касоморфина, киоторфина и их биоактивных фрагментов.
15. Способ по п. 7 или 8, в котором терапевтическое соединение является антагонистом опиата.
16. Способ по п. 15, в котором антагонист опиата выбирают из группы, состоящей из налоксона и налтрексона.
17. Способ по п. 7 или 8, в котором терапевтическое соединение является нейротропным фактором.
18. Способ по п. 17, в котором нейротропный фактор выбирают из группы, состоящей из инсулиноподобного фактора роста, реснитчатого нейротропного фактора, факторов роста нервов, допамина, эпинефрина, норепинефрина, гамма-аминомасляной кислоты и неостигмина.
19. Способ по п. 1, в котором систему доставки лекарственного средства вводят через эпидуральный катетер.
20. Способ по п. 19, в котором эпидуральный катетер вставляют вниз из цервикальной области.
21. Способ по п. 1, в котором систему доставки лекарственного средства вводят через иглу для подкожных инъекций, вставленную в эпидуральное пространство.
22. Способ уменьшения угнетения дыхания у пациента, которому введено анальгезирующее соединение, включающий эпидуральное введение пациенту разовой дозы анальгезирующего соединения, инкапсулированного в липосомную лекарственную форму с длительным высвобождением.
23. Способ по п. 22, в котором липосомная лекарственная форма содержит мультивезикулярные липосомы.
24. Способ по п. 23, в котором анальгезирующее соединение является опиоидом.
25. Способ по п. 24, в котором опиоид является морфинсульфатом.
26. Способ по п. 24, в котором опиоид выбирают из группы, состоящей из гидроморфона, кодеина, гидрокодона, леворфанола, оксикодона, оксиморфона, диацетилморфина, бупренорфина, налбупина, буторфанола, пентазоцина, метадона, фентанила, суфентанила и алфентанила.
27. Способ по п. 25, в котором доза содержит от примерно 1 до 60 мг морфинсульфата.
28. Способ по п. 1, в котором система доставки лекарственного средства содержит полимерную матрицу.
29. Способ по п. 28, в котором система доставки лекарственного средства является недисперсной.
30. Способ по п. 28, в котором полимерную матрицу выбирают из группы, состоящей из полилактида, полигликолида, сложного полиэфира, полиуретана, полиамида и их комбинаций.
31. Способ по п. 29, в котором полимерная матрица находится в форме, выбранной из группы, состоящей из сферы, цилиндра и пластины.
32. Способ по п. 28, в котором система доставки лекарственного средства является дисперсной системой.
33. Способ по п. 32, в котором полимерная матрица находится в виде микросфер.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/502,569 US5931809A (en) | 1995-07-14 | 1995-07-14 | Epidural administration of therapeutic compounds with sustained rate of release |
US08/502,569 | 1995-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98102450A true RU98102450A (ru) | 2000-01-27 |
RU2215522C2 RU2215522C2 (ru) | 2003-11-10 |
Family
ID=23998405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98102450/14A RU2215522C2 (ru) | 1995-07-14 | 1996-07-12 | Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания |
Country Status (13)
Country | Link |
---|---|
US (2) | US5931809A (ru) |
EP (2) | EP0839027A4 (ru) |
JP (4) | JP4592119B2 (ru) |
KR (2) | KR20060012027A (ru) |
CN (1) | CN1085944C (ru) |
AU (1) | AU699177B2 (ru) |
BR (1) | BR9609717A (ru) |
CA (1) | CA2226870C (ru) |
HK (1) | HK1014881A1 (ru) |
NO (1) | NO326261B1 (ru) |
NZ (1) | NZ312963A (ru) |
RU (1) | RU2215522C2 (ru) |
WO (1) | WO1997003652A1 (ru) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6123956A (en) * | 1997-07-10 | 2000-09-26 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
US6306432B1 (en) * | 1997-09-08 | 2001-10-23 | Chiron Corporation | High and low load formulations of IGF-I in multivesicular liposomes |
JP4467789B2 (ja) | 1997-09-18 | 2010-05-26 | パシラ ファーマシューティカルズ インコーポレーテッド | 持続放出性リポソーム麻酔組成物 |
IL135989A0 (en) | 1997-11-14 | 2001-05-20 | Skyepharma Inc | Processes for the production of multivesicular liposomes |
CA2340118C (en) * | 1998-08-12 | 2009-01-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
AU780194B2 (en) * | 1999-06-24 | 2005-03-10 | Kyowa Hakko Kirin Co., Ltd. | Method of regulating leakage of drug encapsulated in liposomes |
HU230828B1 (en) * | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
WO2001085093A2 (en) | 1999-12-23 | 2001-11-15 | Neurochem, Inc. | Compounds and methods for modulating cerebral amyloid angiopathy |
US7172871B1 (en) | 2000-09-07 | 2007-02-06 | Children's Medical Center Corporation | Methods and compositions for modulating axonal outgrowth of central nervous system neurons |
PT1337239E (pt) * | 2000-11-30 | 2010-01-26 | Vectura Ltd | Partículas servindo à preparação de uma composição farmacêutica |
EP1920763B2 (en) | 2000-11-30 | 2022-06-15 | Vectura Limited | Pharmaceutical compositions for inhalation |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US8708993B1 (en) * | 2003-10-15 | 2014-04-29 | Physician Technologies, Inc. | Infusion catheter procedure and system |
US8912144B2 (en) | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
ATE401054T1 (de) * | 2004-06-04 | 2008-08-15 | Camurus Ab | Flüssige depotformulierungen |
US20070110674A1 (en) * | 2005-07-29 | 2007-05-17 | Yuhong Xu | Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems |
US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
CA2661302A1 (en) * | 2006-08-16 | 2008-02-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of opioid analgesics |
US8956642B2 (en) * | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
US8475823B2 (en) * | 2008-04-18 | 2013-07-02 | Medtronic, Inc. | Baclofen formulation in a polyorthoester carrier |
CN106913874A (zh) * | 2010-02-22 | 2017-07-04 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
CN102462662A (zh) * | 2010-08-16 | 2012-05-23 | 重庆富进生物医药有限公司 | 脂质体包裹重组人睫状神经营养因子 |
WO2012091054A1 (ja) * | 2010-12-27 | 2012-07-05 | テルモ株式会社 | リポソーム組成物およびその製造方法 |
WO2012118796A1 (en) | 2011-02-28 | 2012-09-07 | The Schepens Eye Research Institute, Inc. | Compositions for controlling neuronal outgrowth |
EP2846773A4 (en) | 2012-05-10 | 2015-12-30 | Painreform Ltd | DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF |
DK2864360T3 (en) | 2012-06-25 | 2017-12-18 | Brigham & Womens Hospital Inc | TARGETED THERAPY |
CN104661648B (zh) | 2012-07-26 | 2019-04-05 | 卡姆拉斯公司 | 阿片样物质制剂 |
JP6698015B2 (ja) | 2013-03-12 | 2020-05-27 | ザ ジェネラル ホスピタル コーポレイション | 疾患の治療のための改変されたミュラー管抑制物質(mis)タンパク質およびその使用 |
BR112015021586B1 (pt) | 2013-03-14 | 2023-01-31 | Fresenius Kabi Deutschland Gmbh | Formulação de morfina farmacêutica injetável e kit |
EP3424547A1 (en) | 2013-03-14 | 2019-01-09 | Fresenius Kabi Austria GmbH | Packaging system for oxygen-sensitive drugs |
US11135269B2 (en) | 2013-12-11 | 2021-10-05 | The General Hospital Corporation | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation |
GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
WO2019071245A1 (en) | 2017-10-06 | 2019-04-11 | Foundry Therapeutics, Inc. | IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS |
KR102168204B1 (ko) | 2018-11-30 | 2020-10-20 | 동국제약 주식회사 | 서방형 리포좀 제제의 제조방법 |
WO2021011299A1 (en) * | 2019-07-12 | 2021-01-21 | Pacira Pharmaceuticals, Inc. | Multivesicular liposome formulations of dexmedetomidine |
US20220313686A1 (en) * | 2019-08-12 | 2022-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pharmaceutical compositions comprising a combination of opioid antagonists |
WO2021141956A1 (en) * | 2020-01-06 | 2021-07-15 | Pacira Pharmaceuticals, Inc, | Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions |
CN115297854A (zh) | 2020-01-10 | 2022-11-04 | 帕西拉制药股份有限公司 | 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛 |
CN115515581A (zh) | 2020-01-10 | 2022-12-23 | 帕西拉制药股份有限公司 | 通过给予缓释脂质体麻醉组合物治疗疼痛 |
BR112023013685A2 (pt) * | 2021-01-11 | 2023-11-14 | Pacira Pharmaceuticals Inc | Tratamento da dor no quadril com composições anestésicas lipossômicas de liberação sustentada |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
KR20220125027A (ko) | 2021-03-04 | 2022-09-14 | 포항공과대학교 산학협력단 | 부피바카인 리포좀 기반의 리포좀 약물전달체 제조방법 및 이에 의해 제조된 서방형 제제 |
WO2022197899A2 (en) | 2021-03-19 | 2022-09-22 | Pacira Pharmaceuticals, Inc. | Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions |
CN114949220B (zh) * | 2022-01-30 | 2023-09-22 | 浙江大学 | 一种靶向损伤节段背根神经节的pH响应镇痛药及其应用 |
US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US35192A (en) * | 1862-05-06 | Improved nutmeg-grater | ||
CH588887A5 (ru) * | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
US4897308A (en) * | 1975-06-30 | 1990-01-30 | L'oreal | Compositions comprising aqueous dispersions of lipid spheres |
US4078052A (en) * | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
US4086257A (en) * | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
CH624011A5 (ru) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4310506A (en) * | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
JPS55153713A (en) * | 1979-05-02 | 1980-11-29 | Kureha Chem Ind Co Ltd | Pharmaceutical preparation of ribosome containing active substance |
US4452025A (en) | 1979-07-18 | 1984-06-05 | Lew Hyok S | Self-interlocking grille |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4394372A (en) * | 1980-12-22 | 1983-07-19 | The Procter & Gamble Company | Process for making lipid membrane structures |
US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4588578A (en) * | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
US4578384A (en) | 1984-02-15 | 1986-03-25 | The United States Of America As Represented By The Secretary Of The Army | Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4696258A (en) | 1984-04-04 | 1987-09-29 | The Magrath Company | Method and substance for the detection of cows in estrus |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
JPH0645396B2 (ja) | 1985-09-04 | 1994-06-15 | ザ・コカ−コ−ラ・カンパニ− | 接続装置 |
IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
FR2592791A1 (fr) * | 1986-01-14 | 1987-07-17 | Ire Celltarg Sa | Composition pharmaceutique, contenant un anesthesique local et/ou un analgesique central encapsule dans des liposomes |
US5244678A (en) * | 1986-01-14 | 1993-09-14 | Ire-Celltarg S.A. | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes |
IL78826A (en) * | 1986-05-19 | 1991-05-12 | Yissum Res Dev Co | Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US4752425A (en) * | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
GB8704171D0 (en) * | 1987-02-23 | 1987-04-01 | Clayton Found Res | Multivesicular liposomes |
JP2666345B2 (ja) * | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
US5261903A (en) * | 1988-04-11 | 1993-11-16 | M.D. Inc. | Composite anesthetic article and method of use |
JPH0660099B2 (ja) * | 1988-04-27 | 1994-08-10 | ベーカー ノートン ファーマシューティカルズ インコーポレイテッド | 麻薬性鎮痛薬を硬膜外投与した際に生じるそう痒症および尿閉を軽減させるための非経口投与剤 |
BE1001869A3 (fr) * | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US4921853A (en) * | 1988-11-14 | 1990-05-01 | Michigan State University | Method for producing analgesia in mammals |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5227165A (en) * | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
SE8904298D0 (sv) | 1989-12-21 | 1989-12-21 | Astra Ab | New compounds |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5246707A (en) * | 1990-04-26 | 1993-09-21 | Haynes Duncan H | Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes |
US5091187A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
USRE35192E (en) | 1990-11-13 | 1996-03-26 | Phoenix Surgical Products, Inc. | Post-surgical anesthesia at a continuous and progressively decreasing administration rate |
CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
ATE165977T1 (de) * | 1991-12-30 | 1998-05-15 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
ATE154240T1 (de) * | 1992-03-12 | 1997-06-15 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
WO1993020802A1 (en) * | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
CA2161225C (en) * | 1993-04-22 | 2003-07-01 | Sinil Kim | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
US5451408A (en) * | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
DE69637021T2 (de) * | 1995-06-27 | 2008-01-10 | Eisai R&D Management Co., Ltd. | Zusammensetzungen zur Erzielung von Analgesie und zur Hemmung der Progression neuropathischer Schmerzerkrankungen |
JP4138874B2 (ja) * | 1995-07-03 | 2008-08-27 | スウェイジロック カンパニー | ばね負荷形ベロー調整器 |
IL165365A0 (en) | 2004-11-24 | 2006-01-15 | Q Core Ltd | Finger-type peristaltic pump |
JP4478127B2 (ja) * | 2006-07-04 | 2010-06-09 | サカエ理研工業株式会社 | 車両用ドアハンドル装置 |
KR101989059B1 (ko) | 2012-08-22 | 2019-06-14 | 삼성디스플레이 주식회사 | 캐스케이드형 화합물 및 이를 포함한 유기 발광 소자 |
-
1995
- 1995-07-14 US US08/502,569 patent/US5931809A/en not_active Expired - Lifetime
-
1996
- 1996-07-12 KR KR1020057023867A patent/KR20060012027A/ko not_active Application Discontinuation
- 1996-07-12 CA CA002226870A patent/CA2226870C/en not_active Expired - Lifetime
- 1996-07-12 RU RU98102450/14A patent/RU2215522C2/ru not_active IP Right Cessation
- 1996-07-12 WO PCT/US1996/011642 patent/WO1997003652A1/en not_active Application Discontinuation
- 1996-07-12 EP EP96924471A patent/EP0839027A4/en not_active Ceased
- 1996-07-12 EP EP08017456.8A patent/EP2036542B1/en not_active Expired - Lifetime
- 1996-07-12 NZ NZ312963A patent/NZ312963A/xx not_active IP Right Cessation
- 1996-07-12 KR KR1019980700208A patent/KR100593722B1/ko not_active IP Right Cessation
- 1996-07-12 AU AU64911/96A patent/AU699177B2/en not_active Ceased
- 1996-07-12 JP JP50535497A patent/JP4592119B2/ja not_active Expired - Lifetime
- 1996-07-12 BR BR9609717-5A patent/BR9609717A/pt not_active Application Discontinuation
- 1996-07-12 CN CN96196697A patent/CN1085944C/zh not_active Expired - Lifetime
-
1997
- 1997-09-16 US US08/931,867 patent/US6428529B1/en not_active Expired - Lifetime
-
1998
- 1998-01-13 NO NO19980146A patent/NO326261B1/no not_active IP Right Cessation
-
1999
- 1999-01-15 HK HK99100207A patent/HK1014881A1/xx not_active IP Right Cessation
-
2008
- 2008-01-24 JP JP2008013960A patent/JP2008143911A/ja not_active Withdrawn
-
2009
- 2009-10-02 JP JP2009230418A patent/JP2010031030A/ja active Pending
- 2009-10-02 JP JP2009230419A patent/JP2010043104A/ja active Pending
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8936808B1 (en) | 1997-12-22 | 2015-01-20 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US9474750B2 (en) | 1997-12-22 | 2016-10-25 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
US9283216B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9358230B1 (en) | 2001-05-11 | 2016-06-07 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9056051B2 (en) | 2001-05-11 | 2015-06-16 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9084729B2 (en) | 2001-05-11 | 2015-07-21 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9161937B2 (en) | 2001-05-11 | 2015-10-20 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9168252B2 (en) | 2001-05-11 | 2015-10-27 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9511066B2 (en) | 2001-05-11 | 2016-12-06 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9480685B2 (en) | 2001-05-11 | 2016-11-01 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9283221B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9345701B1 (en) | 2001-05-11 | 2016-05-24 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US9655855B2 (en) | 2002-04-05 | 2017-05-23 | Purdue Pharma L.P. | Matrix for sustained, invariant and independent release of active compounds |
US9907793B2 (en) | 2002-04-05 | 2018-03-06 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US10420762B2 (en) | 2002-04-05 | 2019-09-24 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US10258235B2 (en) | 2005-02-28 | 2019-04-16 | Purdue Pharma L.P. | Method and device for the assessment of bowel function |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US9820983B2 (en) | 2009-03-10 | 2017-11-21 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
US10071089B2 (en) | 2013-07-23 | 2018-09-11 | Euro-Celtique S.A. | Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98102450A (ru) | Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания | |
US6569866B2 (en) | Sustained-release nalmefene preparations and method | |
US6913760B2 (en) | Drug delivery composition | |
US7968119B2 (en) | Tamper-proof narcotic delivery system | |
US6103258A (en) | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics | |
US8987290B2 (en) | Use of opioid formulations in needle-less drug delivery devices | |
US20020016331A1 (en) | Method of treating pain using nalbuphine and opioid antagonists | |
JP2004512260A5 (ru) | ||
JP2003514013A (ja) | 医薬組成物 | |
WO1998036728A9 (en) | Sustained analgesia achieved with buprenorphine | |
EP1389092A1 (en) | Abuse-resistant opioid dosage form | |
IL207067A (en) | A system for the transdermal delivery of bioneorphine for pain management | |
AU2002303718A1 (en) | Abuse-resistant opioid dosage form | |
IL173346A (en) | A transdermal dosage form comprising buprenorphine for the treating of withdrawal or abstinence syndrome in a drug dependent or opioid tolerant pregnant woman | |
AU782523B2 (en) | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics | |
IE904473A1 (en) | Method for treatment of cocaine and heroin addiction¹comprising transdermal delivery of buprenorphine | |
US20160213680A1 (en) | Compositions and methods using flumazenil with opioid analgesics for treating pain and/or addiction, and with diversion and/or overdose mitigation | |
Ripamonti et al. | Review articles: Transdermal and inhalatory routes of opioid administration: the potential application in cancer pain | |
WO1998030171A1 (en) | Opiate antagonist implant and process of preparation therefor | |
Schäfer | Opioids in pain medicine | |
Mehendale et al. | Clinical pharmacology of opioids: basic pharmacology | |
CN114601819A (zh) | 一种水合氯醛在抑制阿片类药物复吸中的应用 | |
Giannini et al. | P's and blues: potentiation of propoxyphene withdrawal by a variety of antihistamines | |
JP2005533046A5 (ru) | ||
JP2005529106A5 (ru) |